NATIONAL JEWISH HEALTH
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $39.1M
- Transactions
- 2,351
- Companies
- 40
- Average per transaction
- $16,621
Who reported the payments
| AstraZeneca | $10,018,876 |
| Sanofi | $4,822,225 |
| Boehringer Ingelheim | $3,815,623 |
| Sanofi US Services Inc. | $1,845,914 |
| Insmed, Inc. | $1,841,630 |
| Novartis | $1,651,273 |
| Regeneron | $1,573,133 |
| Vertex | $1,469,863 |
| Genentech, Inc. | $1,424,509 |
| Pfizer | $997,404 |
| Apellis Pharmaceuticals, Inc. | $979,394 |
| Paratek Pharmaceuticals, Inc. | $802,146 |
| E.r. Squibb & Sons, L.L.C. | $788,797 |
| United Therapeutics Corporation | $772,341 |
| Janssen Research & Development, LLC | $507,295 |
| Merck | $499,246 |
| Biocryst Pharmaceuticals, Inc. | $437,902 |
| Eli Lilly | $422,049 |
| GSK | $410,246 |
| Dermavant Sciences, Inc. | $323,050 |
| Agilent Technologies, Inc. | $297,635 |
| LEO Pharma AS | $241,187 |
| Roche Products Limited | $235,770 |
| Janssen Scientific Affairs, LLC | $230,000 |
| CSL Behring | $227,732 |
| Astrazeneca UK Limited | $209,707 |
| Incyte Corporation | $191,623 |
| Regeneron Healthcare Solutions, Inc. | $188,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | $161,448 |
| Amgen | $111,002 |
| Biomarin Pharmaceutical Inc. | $107,380 |
| Bayer | $105,000 |
| Aimmune Therapeutics, Inc. | $104,756 |
| Astellas Pharma Global Development | $75,000 |
| Teva Pharmaceuticals USA, Inc. | $74,508 |
| Bristol Myers Squibb | $70,520 |
| Life Technologies Corporation | $67,846 |
| Mylan Specialty L.p. | $67,500 |
| Gilead | $67,293 |
| NS Pharma, Inc. | $66,729 |